By Micah Maidenberg

AstraZeneca PLC (AZN) said regulators in the U.S. will consider extending uses of its drug Farxiga.

The company said Monday the U.S. Food and Drug Administration accepted a supplemental new-drug application for Farxiga, agreeing to conduct a priority review of the therapy.

Regulators, in the new review, will consider the drug's use to treat patients facing the risk of cardiovascular death or the worsening of heart failure in some patients.

Adults with type two diabetes treat that disease with Farxiga, according to a website for the drug.

Write to Micah Maidenberg at micah.maidenberg@wsj.com

(END) Dow Jones Newswires

January 06, 2020 07:36 ET (12:36 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.